Equity Profile

TVTX

TRAVERE THERAPEUTICS

Health CareBiotechnology$4.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.05

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations of a loss of $0.30. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Continue to focus on developing therapies for rare diseases.
Maintain strong R&D investment to support future product pipelines.
Enhance market presence through strategic partnerships.

Expectations

Wall Street Expectations

Overall, expectations for Travere's upcoming earnings are cautiously optimistic, especially after a string of positive surprises in previous quarters.

Bull Case

If Travere can deliver another earnings surprise and show strong revenue growth, it could significantly boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.05

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

Research and Development (R&D) Spending

N/A

R&D spending reflects the company's commitment to innovation and future product development, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the previous quarters?

Given the company's history of beating EPS estimates, this will be a critical measure of continued financial health and investor confidence.

What are the updates on R&D spending and upcoming product launches?

Investors will be keen to understand how the company plans to sustain growth through innovation and whether it remains committed to its R&D strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Travere's ability to sustain its recent performance, particularly given its strong track record of EPS surprises.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend that may continue.

Options pricing indicates a significant move, reflecting uncertainty that could favor a positive outcome.

Insider selling activity, while notable, does not necessarily reflect the company's long-term potential.

Key Risk

If the EPS exceeds $0.10, it could challenge the consensus view and shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report will be pivotal in determining the company's trajectory, especially in light of its recent performance and market expectations.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bullish case, indicating strong financial performance.

Bear Confirmed If

An EPS below $0.00 would confirm the bearish case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$8.7M

211,102 sh

9 insiders

Net

$8.7M

Net selling

Most Active Insiders· 19 open-market trades

Chief Legal Officer and GCREED ELIZABETH E
$2.1M
Net selling

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests the stock could rise by around 0.68%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 2.16%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of rare disease therapies.
2Details on R&D spending and future product launches.
3Management's outlook on market conditions and competitive landscape.
4Insights into sales performance and customer feedback on existing products.
5Any strategic partnerships or collaborations that may impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.05

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations of a loss of $0.30. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Continue to focus on developing therapies for rare diseases.
Maintain strong R&D investment to support future product pipelines.
Enhance market presence through strategic partnerships.

Expectations

Wall Street Expectations

Overall, expectations for Travere's upcoming earnings are cautiously optimistic, especially after a string of positive surprises in previous quarters.

Bull Case

If Travere can deliver another earnings surprise and show strong revenue growth, it could significantly boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.05

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

Research and Development (R&D) Spending

N/A

R&D spending reflects the company's commitment to innovation and future product development, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the previous quarters?

Given the company's history of beating EPS estimates, this will be a critical measure of continued financial health and investor confidence.

What are the updates on R&D spending and upcoming product launches?

Investors will be keen to understand how the company plans to sustain growth through innovation and whether it remains committed to its R&D strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Travere's ability to sustain its recent performance, particularly given its strong track record of EPS surprises.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend that may continue.

Options pricing indicates a significant move, reflecting uncertainty that could favor a positive outcome.

Insider selling activity, while notable, does not necessarily reflect the company's long-term potential.

Key Risk

If the EPS exceeds $0.10, it could challenge the consensus view and shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report will be pivotal in determining the company's trajectory, especially in light of its recent performance and market expectations.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bullish case, indicating strong financial performance.

Bear Confirmed If

An EPS below $0.00 would confirm the bearish case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$8.7M

211,102 sh

9 insiders

Net

$8.7M

Net selling

Most Active Insiders· 19 open-market trades

Chief Legal Officer and GCREED ELIZABETH E
$2.1M
Net selling

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests the stock could rise by around 0.68%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 2.16%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of rare disease therapies.
2Details on R&D spending and future product launches.
3Management's outlook on market conditions and competitive landscape.
4Insights into sales performance and customer feedback on existing products.
5Any strategic partnerships or collaborations that may impact growth.